From Medscape Oncology

Medscape Medical News from the:

2013 Genitourinary Cancers Symposium (GUCS)

February 14 - 16, 2013; Orlando, Florida

This coverage is not sanctioned by, nor a part of, the American Society of Clinical Oncology,
the American Society for Radiation Oncology, or the Society of Urologic Oncology.

Conference News

GUCS Genomic Test Predicts Metastasis Risk in Prostate Cancer
Medscape Medical News, February 22, 2013
GUCS Comparing Costs of New Drugs in Prostate Cancer
Medscape Medical News, February 21, 2013
GUCS Markers May Indicate Occult High-Grade Prostate Cancer
Medscape Medical News, February 21, 2013
GUCS Addition of Immunotherapy Prolongs Survival in Kidney Cancer
Medscape Medical News, February 20, 2013
GUCS Anticoagulants and Metastatic Castration-Resistant Prostate CA
Reuters Health Information, February 19, 2013
GUCS $32 Million: Cost of Overtreatment of Prostate Cancer
Medscape Medical News, February 13, 2013
GUCS Watchful Waiting Appropriate Tx for Some Renal Tumors
Medscape Medical News, February 12, 2013
GUCS Shorter ADT Appears to Be Best for High-Risk Prostate Cancer
Medscape Medical News, February 12, 2013

Medscape Oncology© WebMD, LLC

Previous GUCS Coverage

2012 Genitourinary Cancers Symposium (GUCS)

2011 Genitourinary Cancers Symposium (GUCS)

2010 Genitourinary Cancers Symposium (GUCS)

All material on this website is protected by copyright, Copyright © 1994-2019 by WebMD LLC. This website also contains material copyrighted by 3rd parties.